Development Of A Safe Live Genetically Attenuated Blood Stage Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$822,191.00
Summary
Malaria presents an enormous global health problem, and also has a significant impact on social and economic development in countries where the disease is endemic. Our project will produce a live genetically-modified vaccine against Plasmodium falciparum, the parasite that causes the form of malaria mostly deadly to humans. Our development plan will include the first ever clinical trials of a malaria vaccine of this kind and will look at vaccine safety and effectiveness.
Proteasome Inhibitors As Reversers Of Resistance To Artemisinin-based Antimalarials
Funder
National Health and Medical Research Council
Funding Amount
$473,534.00
Summary
Current antimalarial control is highly dependent on Artemisinin Combination Therapy (ACTs), which makes recent reports of decreased clinical efficacy of artemisinins extremely concerning. This project will develop proteasome inhibitors to synergise the activity of artemisinins - effectively reversing resistance. We will confirm that the selected compounds have good bioavailability, low cytotoxicity in human cell lines and efficacy in mouse models of malaria.
Formulation Of A Pan-species, Multi-stage Vaccine For The Malaria Eradication Agenda
Funder
National Health and Medical Research Council
Funding Amount
$777,611.00
Summary
GNT 1093311 entitled 'Formulation of a pan-species, multi-stage vaccine for the malaria eradication agenda' seeks to undertake the preclinical development of a saccharide conjugate vaccine directed towards all major species and stages of malaria. The objectives are: (i) to undertake the synthesis of the vaccine construct; (ii) to compare immunogenicity, formulation and efficacy of various vaccine constructs with a view to down-selecting the optimal combination to take to human clinical trial.